Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
Clinical trial NCT05512351 · RECRUITING
Trial details
- NCT number
- NCT05512351
- Sponsor
- Henan Provincial People's Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-23
- Primary completion
- 2024-12-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.